Trials / Terminated
TerminatedNCT01312935
Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
A Phase 2 Proof of Concept Study of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- PolyMedix, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Detailed description
PMX-60056 is being developed as a rapid and effective reversal agent for use in those situations where anticoagulation by heparin, or LMWH must be quickly stopped. Potential uses include reversal of anticoagulation induced to prevent clotting during surgical procedures, and rescue from cases of inadvertent or unexpected overdose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PMX-60056 | investigational drug |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-06-01
- Completion
- 2012-08-01
- First posted
- 2011-03-11
- Last updated
- 2012-05-17
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01312935. Inclusion in this directory is not an endorsement.